TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
The Buck Institute and Georgetown University are co-leading SEEDS, a four-year research effort backed by an ARPA-H award of up to $51.7 million. The consortium will combine computational models and experiments to study how intrinsically disordered proteins change under different cellular conditions, initially focusing on Alzheimer’s disease and Ewing sarcoma.
The Buck Institute for Research on Aging and Georgetown University are co-leading a four-year consortium that has received an award of up to $51.7 million from ARPA-H to study how flexible proteins shift toward harmful states before disease-related damage occurs. The effort, called SEEDS, will pair artificial-intelligence and computational approaches with laboratory experiments, initially examining Alzheimer’s disease and Ewing sarcoma.
SEEDS stands for Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale. It brings together researchers from nine academic institutions and seven industry partners, combining expertise in protein science, computational modeling, AI, cancer and neuroscience. Georgetown’s Priyanka Joshi and the Buck Institute’s Chuankai (Kai) Zhou are co-leading the effort.
The consortium will study intrinsically disordered proteins, which do not settle into one stable three-dimensional shape. Instead, they can take multiple forms, with their behavior affected by conditions inside cells, including acidity, molecular crowding, metals, metabolites and chemical modifications. The team aims to connect a protein’s sequence and surroundings to the shapes and behaviors it adopts.
Researchers plan to compare computational predictions against experimental measurements of protein behavior under different conditions. The project is intended to build a platform for predicting when proteins may move from healthy functional states toward disease-associated ones, and to explore whether those changes can be detected or redirected. The award is for up to $51.7 million; the source does not specify how much will ultimately be disbursed.
Reading Early Protein Changes
Protein misfolding and aggregation are associated with Alzheimer’s disease, ALS, some cancers and other chronic or degenerative conditions. The project focuses on changes that may occur before proteins clump together and cause lasting cellular damage, a stage the ARPA-H program describes as an early point for studying protein dysfunction.
Many proteins implicated in these processes are difficult to target with conventional medicines because they lack stable shapes and familiar drug-binding pockets. If SEEDS can make their behavior more predictable, that could help researchers identify measurable changes and investigate possible intervention points. These are aims, not established clinical outcomes: the announcement does not report a diagnostic test, treatment, or demonstrated benefit for patients.
The approach also addresses a data gap. AI tools such as AlphaFold have benefited from large collections of protein-structure information, while researchers have less comparable structural data for disordered proteins. SEEDS intends to gather information at scale and use experiments to test whether its models describe what proteins actually do.
intrinsically disordered protein research kits
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Why Disordered Proteins Are Difficult
Many proteins adopt relatively stable structures that researchers can study and, in some cases, target with drugs designed to fit particular binding pockets. Intrinsically disordered proteins behave differently: they form ensembles of shapes rather than one fixed structure. Their flexibility supports normal cell functions, but it complicates efforts to describe what changes when a protein begins to behave abnormally.
Researchers can capture snapshots of these proteins, often after they have already clumped, but the source report says they cannot reliably predict how the proteins will behave as cellular conditions change or when a shift first becomes harmful. SEEDS is designed to move beyond studying proteins one at a time by linking sequence, cellular environment and behavior across a larger set of observations.
The consortium combines two groups, Georgetown’s INTREPID and the Buck Institute’s SHIFT. It is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention program, or BIOGAMI, led by ARPA-H Program Manager Shannon Greene. BIOGAMI centers on the early stages of protein dysfunction and uses the idea of a molecular “grammar” to describe rules that could govern protein behavior.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
What the Award Will Establish
The award supports a research program, but the announcement does not show that SEEDS can yet predict harmful changes reliably, identify a clinically useful warning signal or alter the course of disease. It also does not provide a breakdown of the award by institution, a schedule of research milestones, or details about how the maximum award amount will be allocated.
The source identifies Alzheimer’s disease and Ewing sarcoma as the initial focus but does not specify which proteins will be studied first, what measures will be used to judge model accuracy, or when results are expected. The extent to which findings from these conditions could apply to other diseases associated with protein misfolding also remains unknown.
Testing Models Against Experiments
Over the four-year effort, SEEDS researchers are expected to develop and test ways to map disordered-protein behavior across sequences and cellular conditions. A central next step is comparing physics-guided AI predictions with experimental measurements and refining the models where results differ.
The source report does not give dates for the first data releases, published findings or potential diagnostic and treatment studies. The near-term measure of progress will be whether the consortium can produce reproducible predictions that match experiments; any later use in clinical care would require further research and validation.
Key Questions
What is SEEDS?
SEEDS is a four-year research consortium co-led by the Buck Institute and Georgetown University. Its name stands for Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale.
How much funding did the consortium receive?
ARPA-H awarded the effort up to $51.7 million. The source does not state the final amount that will be paid or how funding will be divided among partners.
Which diseases will the team study first?
The initial focus is Alzheimer’s disease and Ewing sarcoma. The report does not name the specific proteins or research milestones for these studies.
Will the project produce a new treatment?
The team hopes its work could support future ways to detect or redirect harmful protein changes, but no treatment or diagnostic has been developed or demonstrated in the announcement. The project is a research effort, and any clinical applications would require additional testing.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
